Loading company…
Synklino is developing therapies to address cytomegalovirus infections in organ transplant patients.
Founded in 2017 and based in Charlottenlund, Denmark, Synklino develops therapies for cytomegalovirus infections in transplant patients. Its candidate SYN002 is intended to treat donor organs before transplantation or patients afterward. In June 2022, the company raised DKK 222 million in Series A funding led by PKA, with Eir Ventures, Maj Invest Equity, and Vaekstfonden.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in